As part of its regular monitoring and its joint initiative with the Council for Responsible Nutrition, the NAD investigated claims for FlexSure, a joint product containing U. tomentosa, B. serrata, L. mevenii, and L-Leucine. See Vital G-Netics/SBB Holdings, Inc., NAD Case No. 5912 (Dec. 21, 2015). The NAD found that the advertiser could make narrowly tailored efficacy and safety claims based on positive results from an eight-week randomized, multi-center, placebo-controlled, double-blind study conducted on the product in India. The NAD also found that the advertiser could support mechanism claims as long as they are qualified to convey that they are based on anin vitro study. The NAD, however, rejected the “clinically proven” establishment claims given that not all results from the eight-week study were positive and, in the NAD’s view, other studies offered by the advertiser lacked either sufficient reliability or sufficient relevance to the product (e.g., an adequate match between FlexSure and the formulations tested). The NAD also rejected testimonial and performance claims suggesting efficacy within seven days.